Effect of Hepatic Impairment on <scp>OATP1B</scp> Activity: Quantitative Pharmacokinetic Analysis of Endogenous Biomarker and Substrate Drugs-Reference-Cited by-同舟云学术

Effect of Hepatic Impairment on OATP1B Activity: Quantitative Pharmacokinetic Analysis of Endogenous Biomarker and Substrate Drugs

Published:2023-01-15 Issue:5 Volume:113 Page:1058-1069
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Lin Jian¹,Kimoto Emi¹^ORCID,Yamazaki Shinji²³^ORCID,Vourvahis Manoli⁴,Bergman Arthur⁵,Rodrigues A. David¹,Costales Chester¹^ORCID,Li Rui⁶,Varma Manthena V. S.¹^ORCID

Affiliation:

1. Pharmacokinetics, Dynamics and Metabolism, Medicine Design Worldwide R&D, Pfizer Inc Groton Connecticut USA

2. Pharmacokinetics, Dynamics and Metabolism, Medicine Design Worldwide R&D, Pfizer Inc. San Diego California USA

3. Drug Metabolism and Pharmacokinetics Janssen Research & Development, LLC San Diego California USA

4. Clinical Pharmacology, Global Product Development Pfizer Inc. New York New York USA

5. Clinical Pharmacology, Early Clinical Development Pfizer Inc. Cambridge Massachusetts USA

6. Pharmacokinetics, Dynamics and Metabolism, Medicine Design Worldwide R&D, Pfizer Inc. Cambridge Massachusetts USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2829

Reference44 articles.

1. Dose Adjustment in Patients with Liver Disease

2. Review article: time to revisit Child‐Pugh score as the basis for predicting drug clearance in hepatic impairment

3. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

4. Dosage adjustment for hepatic dysfunction based on child‐Pugh scores;Spray J.W.;Am. J. Health Syst. Pharm.,2007

5. Evaluation of Hepatic Impairment Dosing Recommendations in FDA-Approved Product Labels

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transporter-mediated drug-drug interactions: regulatory guidelines, in vitro and in vivo methodologies and translation, special populations, and the blood-brain barrier;Drug Metabolism Reviews;2024-07-05

2. Expanding Role of Endogenous Biomarkers for Assessment of Transporter Activity in Drug Development: Current Applications and Future Horizon;Pharmaceutics;2024-06-25

3. Facing the Facts of Altered Plasma Protein Binding: Do Current Models Correctly Predict Changes in Fraction Unbound in Special Populations?;Journal of Pharmaceutical Sciences;2024-06

4. Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B‐CYP2C8 Interplay;Clinical Pharmacology & Therapeutics;2024-02-26

5. A Pilot Study To Assess the Suitability of Riboflavin As a Surrogate Marker of Breast Cancer Resistance Protein in Healthy Participants;Journal of Pharmacology and Experimental Therapeutics;2024-01-31